Literature DB >> 19193658

Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis.

M I Gillham1, S Sundaram, C R Laughton, C S Haworth, D Bilton, J E Foweraker.   

Abstract

OBJECTIVES: To investigate variability in colony morphology and antibiotic susceptibility in populations of Pseudomonas aeruginosa from sputa of patients with bronchiectasis without cystic fibrosis (CF) compared with P. aeruginosa isolated from patients with CF, and from other infections as controls.
METHODS: P. aeruginosa was cultured from 31 patients with non-CF bronchiectasis, 24 with CF, 7 ventilated patients and 9 skin swabs. Four colonies of each morphotype of P. aeruginosa were tested for susceptibility to 12 antibiotics by disc diffusion. The variability in susceptibility between the isolates in each patient's population of P. aeruginosa was investigated.
RESULTS: The classic morphotype of P. aeruginosa was cultured from control samples with an average variation in zone size of 2 mm (range 0-4 mm) for the four colonies tested. Non-CF bronchiectasis sputa contained 1-3 colonial morphotypes of P. aeruginosa; the average difference between the largest and smallest zone sizes found in all examples of the morphotypes present in each sample varied from 3 mm (1-9 mm) for colistin to 8 mm (0-24 mm) for piperacillin/tazobactam. CF sputa contained 2-6 morphotypes of P. aeruginosa with a wider variation of susceptibility. There was variation between bacteria of the same morphotype from non-CF bronchiectasis and CF sputa.
CONCLUSIONS: Phenotypic variation in colonial form and antibiotic susceptibility is not unique to chronic infection in CF but is also found in non-CF bronchiectasis. This questions the use of current susceptibility testing methods for the complex populations of bacteria found in chronic lung infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19193658     DOI: 10.1093/jac/dkp007

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

Review 1.  Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.

Authors:  Axel Dalhoff
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

Review 2.  Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.

Authors:  Michael D Parkins; Ranjani Somayaji; Valerie J Waters
Journal:  Clin Microbiol Rev       Date:  2018-08-29       Impact factor: 26.132

3.  Virulence adaptations of Pseudomonas aeruginosa isolated from patients with non-cystic fibrosis bronchiectasis.

Authors:  Taylor E Woo; Jessica Duong; Nicole M Jervis; Harvey R Rabin; Michael D Parkins; Douglas G Storey
Journal:  Microbiology       Date:  2016-12       Impact factor: 2.777

Review 4.  Revealing the dynamics of polymicrobial infections: implications for antibiotic therapy.

Authors:  Geraint B Rogers; Lucas R Hoffman; Marvin Whiteley; Thomas W V Daniels; Mary P Carroll; Kenneth D Bruce
Journal:  Trends Microbiol       Date:  2010-06-01       Impact factor: 17.079

5.  Efficient photodynamic therapy against gram-positive and gram-negative bacteria using THPTS, a cationic photosensitizer excited by infrared wavelength.

Authors:  Stanislaw Schastak; Svitlana Ziganshyna; Burkhard Gitter; Peter Wiedemann; Thomas Claudepierre
Journal:  PLoS One       Date:  2010-07-20       Impact factor: 3.240

Review 6.  Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.

Authors:  James F Chmiel; Timothy R Aksamit; Sanjay H Chotirmall; Elliott C Dasenbrook; J Stuart Elborn; John J LiPuma; Sarath C Ranganathan; Valerie J Waters; Felix A Ratjen
Journal:  Ann Am Thorac Soc       Date:  2014-09

Review 7.  Antibiotic efficacy in the complex infection environment.

Authors:  L Radlinski; B P Conlon
Journal:  Curr Opin Microbiol       Date:  2017-10-06       Impact factor: 7.934

8.  Heterogeneous Antimicrobial Susceptibility Characteristics in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients.

Authors:  Xuan Qin; Chuan Zhou; Danielle M Zerr; Amanda Adler; Amin Addetia; Shuhua Yuan; Alexander L Greninger
Journal:  mSphere       Date:  2018-03-14       Impact factor: 4.389

9.  Single clinical isolates from acute uncomplicated urinary tract infections are representative of dominant in situ populations.

Authors:  Dana Willner; Serene Low; Jason A Steen; Narelle George; Graeme R Nimmo; Mark A Schembri; Philip Hugenholtz
Journal:  MBio       Date:  2014-02-25       Impact factor: 7.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.